Genmab A/S (GNMSF)
Develops antibody drugs to treat cancer, blood disorders, and autoimmune diseases.
$282.00+0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+26.9%
The outlook
GNMSF is trading near the middle of its 52-week range with a mixed price trend relative to its moving averages. The stock carries a neutral analyst lean and trades at a trailing P/E of 21.4. Coverage data is not provided, so the overall analyst outlook remains unclear.
What’s behind the score
Price trendMixed vs its moving averages
52-week range48% of the way from its 52-week low to high
Market cap
$17.31B
52-wk high
$352.00
52-wk low
$216.31
50-day avg
$264.06
200-day avg
$290.77
Trailing P/E
21.4